I’m Eyeing 2 Biopharma Stocks Amid Choppy Market Action
These small-cap biotechs offer core businesses that fund a much bigger opportunity.
Inseego Reports, and My Question Is: What Was I Thinking?!
Here’s how I’m handling this holding after a dismal report … and why I’m adding to another name that has the right ‘ingredients.’
The Surprising Tesla-SpaceX Correlation Investors Can’t Ignore
Tesla and SpaceX share more than a CEO. Here’s what SpaceX’s lockup expiration could mean for Tesla stock.
Blowoff Tops Are Rare. But Is That What We’re Seeing Now?
With few people willing to admit they’re bearish, are we nearing a top in the market?
I See Two Very Different Opportunities in This Overbought Market
I’m getting into a legacy technology stock and an up-and-coming biopharma. Here’s why.
Here’s My AMD Plan After Wall Street’s ‘Misguided’ Selloff
What exactly are AMD bears hanging their hats on? Oh, and I have allies…
Buying More Rocket Lab After $397 Million Update
The aerospace firm has been awarded a significant contract by the U.S. Space Force.
Options Traders Bullish, But Fewer Stocks Hit New Highs. Is the Rally Sustainable?
The speed with which options traders have turned bullish is a little too quick for comfort. Will we reach overbought before backing off?
This Legacy Tech Name Is Suddenly of the Cheapest AI Plays Around
Earnings growth better than 50%, a forward multiple around 12 and an analyst target roughly a third higher.